Showing results (151-160 of 174) with videos related to

Sort By:
Pageof 18
The Lancet. Diabetes & Endocrinology|June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 studyVivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
Cancer Research Communications|September 15, 2023
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other TumorsGlenn J Hanna, Anastasios Stathis, Elena Lopez-Miranda, et al.
JCO Precision Oncology|August 23, 2024
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With PembrolizumabAlberto Hernando-Calvo, S Y Cindy Yang, Maria Vila-Casadesús, et al.
The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.
Molecular Oncology|March 20, 2023
Engaging European society at the forefront of cancer research and care: How discussions at the 5th Gago Conference on European Science policy led to the Heidelberg ManifestoMichael Baumann, Julio Celis, Ulrik Ringborg, et al.
BMC Cancer|July 22, 2024
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancerAlexandra Leary, Purificación Estévez-García, Renaud Sabatier, et al.
Nature Cancer|February 28, 2022
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncologyDavid Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, et al.
Radiology|January 26, 2021
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid TumorsMarta Ligero, Alonso Garcia-Ruiz, Cristina Viaplana, et al.
The New England Journal of Medicine|August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C MutationAdrian Sacher, Patricia LoRusso, Manish R Patel, et al.
Oncoimmunology|January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignanciesChia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
Pageof 18